Earnings call transcript: HydrogenPro posts wider q2 2026 loss as stock falls

HydrogenPro reported Q2 2026 revenue of NOK 15m and a net loss of NOK 51m (EBITDA -NOK 16m), with losses still weighing on the turnaround despite cost discipline. Backlog rose to NOK 262m (+NOK 10m sequentially) and cash increased to NOK 59m after capital raises totaling NOK 21m, but the company also booked a NOK 32m impairment tied to its Tianjin restructuring and OEM shift with LONGI. Shares fell 7.38% to $0.55 as investors stayed cautious on delayed project final investment decisions and continued unprofitability, even as management maintained confidence in 2026–2027 FIDs and targeted eventual profitability.

Analysis

This is less a “green hydrogen demand” print than a capital-structure and execution story. The business is drifting from an owned-manufacturing model toward a thinner, more commoditized OEM layer, which usually compresses gross margin but also reduces asset intensity; in practice, that shifts the equity from an operating turnaround toward an optionality bet on third-party project conversion. In the near term, that is negative for valuation because the market will discount backlog unless it sees repeatable order conversion and evidence that the leaner cost base can outrun dilution.

The second-order winner is not the company itself but the capital providers and strategic industrial partners that can bundle financing, EPC support, and customer access. If policy-supported projects eventually clear FID, the value will accrue to firms with balance-sheet capacity and bankability rather than small single-product vendors; that argues for relative preference in larger industrial gas / equipment names over microcap electrolyzer exposure. The losers are smaller peers without funded pipelines, because each quarter of delay raises the probability that customers consolidate around a few financially durable suppliers.

Catalyst path is two-speed: over days, this is mostly a liquidity-and-dilution trade; over 1-3 months, watch for any strategic-investor announcement or order conversion that changes runway math; over 6-18 months, the thesis only improves if end-market regulation turns into actual FIDs. The contrarian angle is that the stock may already be pricing a near-death scenario: if the backlog converts and the company avoids another raise for two quarters, the equity can rally hard on low float. But that requires proof, not narrative. Falsifiers: meaningful order intake, improved gross margin ex-restructuring, or a non-dilutive strategic financing that extends cash coverage beyond four quarters.

Key Decisions for Investors

• Avoid initiating fresh long exposure in HYPRF here; wait for either a financing announcement or a clear order-conversion print. This is a low-quality setup until cash runway and dilution terms are visible.
• If liquidity allows, use any spike on strategic-review headlines to short HYPRF into strength; the risk/reward still skews negative as long as project FIDs remain delayed and repeated capital raises are likely within 1-2 quarters.
• Relative-value idea: long LIN or APD vs. short HYPRF as a ‘bankable hydrogen picks-and-shovels’ pair. The long leg benefits if hydrogen projects eventually fund; the short leg is exposed to margin compression and financing overhang.
• Watch for a closing move above ~$0.80 on volume or a quarter with materially better backlog conversion; that would force a reassessment of the bear case and likely squeeze short interest in a thin name.
• Treat a strategic-investor transaction as the key catalyst, not the technology narrative. If the deal is purely equity-dilutive, fade it; if it includes customer/offtake alignment or non-dilutive funding, the trade becomes much more interesting.